Next Article in Journal
Estimating the Risk of COVID-19 Death during the Course of the Outbreak in Korea, February–May 2020
Next Article in Special Issue
Identification of a miRNA Based-Signature Associated with Acute Coronary Syndrome: Evidence from the FLORINF Study
Previous Article in Journal
Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease
Previous Article in Special Issue
Association of Circulating microRNAs with Coronary Artery Disease and Usefulness for Reclassification of Healthy Individuals: The REGICOR Study
Open AccessArticle

Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study

Department of Cardiology, Medical University of Białystok, 15-276 Białystok, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 1640; https://doi.org/10.3390/jcm9061640
Received: 25 April 2020 / Revised: 23 May 2020 / Accepted: 25 May 2020 / Published: 29 May 2020
Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD after acute myocardial infarction (AMI). The analysis included 110 patients who were hospitalized due to AMI, treated with primary coronary intervention (PCI) and further attended a follow-up visit, and 100 healthy volunteers. The Gal-3 concentration and carotid ultrasound were evaluated at baseline and on a follow-up visit. We found that the Gal-3 concentration in the group with hyperlipidemia decreased during the observation (10.7 vs. 7.9 ng/mL, p = 0.00003). Patients rehospitalized during follow up had higher concentration of Gal-3 in the acute phase of myocardial infarction (MI) (10.7 vs. 7.2 ng/mL, p = 0.02; 10.1 vs. 8.0 ng/mL, p = 0.002, respectively). In the group of patients who had none of the following endpoints: subsequent MI, PCI, coronary artery bypass grafting (CABG) or stroke, there was a decrease in Gal-3 concentration at the follow-up visit. Parameters affecting the frequency of a composite endpoint occurrence are: the presence of atheromatous plaque in the carotid artery (p = 0.017), Gal-3 (p = 0.004) and haemoglobin (p = 0.03) concentration. In multivariate analysis, only Gal-3 concentration higher than 9.2 ng/mL at discharge was associated with a nine-fold increase of risk of composite endpoint occurrence (p = 0.0005, OR = 9.47, 95% CI 2.60–34.45). A significant decrease in Gal-3 concentration was observed in the group of patients after AMI without the endpoint occurrence during observation. View Full-Text
Keywords: galectin-3; coronary artery disease; atherosclerosis; carotid arteries galectin-3; coronary artery disease; atherosclerosis; carotid arteries
Show Figures

Figure 1

MDPI and ACS Style

Święcki, P.; Sawicki, R.; Knapp, M.; Kamiński, K.A.; Ptaszyńska-Kopczyńska, K.; Sobkowicz, B.; Lisowska, A. Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study. J. Clin. Med. 2020, 9, 1640.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop